|
| INDUSTRY
NEWS |
|
NEW: StemSpan™ ACF, the First Plasma Component-Free Hematopoietic Expansion
Media
STEMCELL Technologies Inc.
announced this week the launch of StemSpan™ ACF, a new animal component-free (ACF) and chemically-defined
hematopoietic stem cell expansion medium, which contains no animal and human plasma-derived components.
[STEMCELL Technologies Inc.] Press
Release
ARIAD Announces Initiation of Randomized Phase III Trial of Ponatinib in Newly
Diagnosed Patients with Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. announced the initiation of the randomized Phase III trial of
ponatinib in adult patients with newly diagnosed chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc.]
Press
Release
Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial
of Lead Product Candidate Liposomal Grb-2 in Leukemias
Bio-Path Holdings, Inc. announced that it has begun enrolling patients into the
fourth dosage cohort in its Phase I clinical trial of BP-100.1.01 (Liposomal Grb-2), which is being
evaluated as a systemic treatment for blood cancers including acute myeloid leukemia, chronic myelogenous
leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome. [Business Wire] Press
Release
American Society of Hematology Launches Multi-Million-Dollar Grant
Program to Support Critical Blood Disease Research
The American Society of Hematology announced its commitment of $9 million over a three-year
period to provide funding, in the form of bridge grants, for its hematologists whose vital research will
not be accomplished due to the severe funding reductions for biomedical research. [American Society of
Hematology] Press Release
Stem Cell Agency Commits $150 Million to Develop New
Therapies
California’s stem cell
agency, the California Institute for Regenerative Medicine approved $150 million in new funding to help
move promising stem cell-based therapies from the laboratory research phase to clinical trials in people.
[California Institute for Regenerative Medicine] Press
Release
Cleveland BioLabs
Signs Contract for Approximately $4 Million with Russian Ministry of Industry and Trade for Development of
CBLB612
Cleveland BioLabs, Inc.
announced that it has signed a contract valued at approximately $4 million, with the Ministry of Industry
and Trade of the Russian Federation for development of CBLB612, a drug in development for stimulation of
hematopoietic stem cell proliferation and mobilization. [Cleveland BioLabs, Inc.] Press
Release
DACOGEN® Receives Positive Regulatory Recommendation in the European Union
for Treatment of Acute Myeloid Leukemia
Janssen-Cilag
International NV announced that the Committee for Medical Products for Human Use (CHMP) of the European
Medicines Agency has granted a positive opinion recommending approval of DACOGEN® for injection. The CHMP
is recommending that DACOGEN be indicated for the treatment of adult patients with newly diagnosed de
novo or secondary acute myeloid leukemia, who are not candidates for standard induction chemotherapy.
[Business Wire] Press
Release
|
|
| JOB
OPPORTUNITIES |
|
Quality Control Operations Coordinator
(STEMCELL Technologies, Inc.)
Research Associate – Chemistry (STEMCELL Technologies, Inc.)
Research Associate – Particle Chemistry (STEMCELL Technologies,
Inc.)
Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)
Research Technologist – Media Development (STEMCELL Technologies,
Inc.)
Research Technologist – Research and Development (STEMCELL Technologies, Inc.)
Scientist – Induced Pluripotent Stem Cells (STEMCELL
Technologies, Inc.)
Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)
Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)
Postdoctoral Position
– Hematopoietic Stem Cell Biology and Immunology (University of California, San Francisco)
Postdoctoral Positions – Stem Cells and Immunology (University of
Connecticut)
Postdoctoral Position – Stem Cells (Children’s
Hospital of Chicago Research Center)
Recruit Top
Talent: Reach more
than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job
Board at no
cost.
|
|
|
|
